Hemodez-H (Haemodes-N)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePotassium Chloride + Calcium Chloride + Magnesium Chloride + Sodium Hydrocarbonate + Sodium Chloride + Povidone-8 Thousand.Potassium Chloride + Calcium Chloride + Magnesium Chloride + Sodium Hydrocarbonate + Sodium Chloride + Povidone-8thousand
Similar drugsTo uncover
  • Hemodez-8000
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Hemodez-H
    solution d / infusion 
    MAKSFARM, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    MOSFARM, LLC    
  • Hemodez-H
    solution d / infusion 
    ESKOM NPK, OAO     Russia
  • Hemodez-H
    solution d / infusion 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    Kursk Biofactory - BIOK, FKP     Russia
  • Hemodez-H
    solution d / infusion 
    RESTER, CJSC     Russia
  • Hemodez-H
    solution d / infusion 
    ELFARMI, LTD.     Russia
  • Hemodez-H
    solution d / infusion 
    PHARMSTANDART-UFIM VITAMIN FACTORY, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    DALHIMFARM, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    ATOLL, LLC     Russia
  • Krasgemodez 8000
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Krasgemodez 8000
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Neohemodes
    solution in / in 
    SYNTHESIS, OJSC     Russia
  • Neohemodes
    solution inwards 
    FIRM MEDPOLIMER, JSC     Russia
    • Dosage form: & nbspsolution for infusions
    Composition:

    1 liter of the solution contains povidone (low molecular weight polyvinylpyrrolidone 8000 ± 2000 in terms of anhydrous) - 60.0 g, sodium chloride - 5.50 g, potassium chloride - 0.42 g,calcium chloride hexahydrate 0.50 g, magnesium chloride hexahydrate 0.005 g, sodium bicarbonate 0.23 g, water for injection up to 1 l.

    Description:Transparent liquid of yellow color.
    Pharmacotherapeutic group:Detoxifying agent
    ATX: & nbsp

    B.05.A.A   Blood plasma preparations and plasma-substituting drugs

    Pharmacodynamics:

    The action of Hemodesa-H is due to the ability of low molecular weight polyvinylpyrrolodinone to bind toxins that circulate in the blood and quickly remove them from the body. Hemodez-H differs from Hemodesa by a lower molecular weight of polyvinylpyrrolidone. The decrease in the molecular weight of the polymer accelerates the excretion of it by the kidneys from the body and improves the detoxification properties of the preparation. It increases renal blood flow, increases glomerular filtration and increases diuresis.

    Pharmacokinetics:

    Metabolic transformations in the body are not affected. Quickly excreted by the kidneys, within 4 hours 80% are output, and after 12-24 hours - completely.

    Indications:

    Shock (post-traumatic, postoperative, burn, hemorrhagic), intoxication (toxic diseases of the gastrointestinal tract: dysentery, dyspepsia, salmonellosis; as a means of detoxification in the postoperative period with peritonitis; liver disease, accompanied by the development of liver failure; intestinal obstruction; thyrotoxicosis; burn disease; acute radiation sickness; sepsis; pneumonia; acute phase of myocardial infarction; hemolytic disease of newborns; intrauterine infection and toxemia of newborns; Toxicosis of pregnant women.

    Contraindications:

    Increased sensitivity to the drug, intracranial hypertension, hemorrhagic stroke, post-traumatic brain injury, cardiovascular failure IIb-III degree, asthma, respiratory insufficiency, severe allergic reactions, phlebothrombosis, thromboembolism, oliguria, anuria, acute nephritis.

    Carefully:Not described.
    Pregnancy and lactation:Not described.
    Dosing and Administration:

    Intravenously drip (40-80 cap / min), through a system with a filter. The dose depends on the age of the patient and the severity of intoxication. Single dose for adults - 200-500 ml; for children - 5.10 ml / kg (maximum single dose for infants - 50-70 ml (2.5 ml / kg), 2-5 years - 100 ml, 5-10 years - 150 ml, 10-15 years - 200 ml).The drug is administered once or repeatedly (up to 2 times a day) for 1-10 days, depending on the severity of intoxication. In acute gastrointestinal infections, burn and radiation diseases are administered 1-2 times a day; with hemolytic disease and toxemia of newborns - 2-8 times a day (daily or every other day); with large focal myocardial infarction (in 1 day) - 200 ml once, with complications for 2 days - 200 ml.

    Side effects:

    With the slow introduction of Haemodesum-H, complications do not usually arise. Introduction with increased speed can cause a decrease in blood pressure, tachycardia, difficulty breathing and require the introduction of vasoconstrictor and cardiac agents, calcium chloride. Individual patients may experience allergic reactions, up to the development of anaphylactic shock. In these cases, you should immediately stop the infusion, conduct symptomatic therapy, (introduce antihistamines, cardiotonic drugs, glucocorticoids, vasopressive drugs).

    Overdose:In case of an overdose, the drug should be withdrawn and symptomatic therapy should be performed.
    Interaction:Not described.
    Special instructions:

    With extensive burns combined with the introduction of plasma, albumin, gamma globulin. Before starting the infusion, the doctor must check the integrity and integrity of the package. The drug should be clear, free of sediment, sediment and mold. The results of visual inspection are recorded in the medical history. Before administration, the solution is warmed to body temperature.

    Effect on the ability to drive transp. cf. and fur:Not described.
    Form release / dosage:

    Solution for infusion.

    Packaging:250 ml in bottles of low-density polyethylene. The bottle, together with the instructions for use, is put in a bag of polyethylene film.

    16 bottles are placed in a box of corrugated cardboard.

    Storage conditions:

    In the dark place at a temperature of 0 ° C to + 20 ° C.

    Keep out of the reach of children.

    Single and repeated freezing at temperatures up to -45 ° C does not affect the quality of the preparation.

    The vials with the frozen solution are kept at room temperature for thawing and mixed.

    Non-wetting of the inner surface of bottles is not a contraindication to the use of the drug.

    Shelf life:

    3 years.Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-006660/08
    Date of registration:15.08.2008
    Expiration Date:Unlimited
    The owner of the registration certificate:MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp21.03.2017
    Illustrated instructions
      Instructions
      Up